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Abstract
Rationale, aims and objectives Many clinical guidelines for cardiovascular disease
(CVD) prevention contain risk estimation charts/calculators. These have shown a tendency
to overestimate risk, which indicates that there might be theoretical ﬂaws in the algorithms.
Total cholesterol is a frequently used variable in the risk estimates. Some studies indicate
that the predictive properties of cholesterol might not be as straightforward as widely
assumed. Our aim was to document the strength and validity of total cholesterol as a risk
factor for mortality in a well-deﬁned, general Norwegian population without known CVD
at baseline.
Methods We assessed the association of total serum cholesterol with total mortality, as
well as mortality from CVD and ischaemic heart disease (IHD), using Cox proportional
hazard models. The study population comprises 52 087 Norwegians, aged 20–74, who
participated in the Nord-Trøndelag Health Study (HUNT 2, 1995–1997) and were
followed-up on cause-speciﬁc mortality for 10 years (510 297 person-years in total).
Results Among women, cholesterol had an inverse association with all-cause mortality
[hazard ratio (HR): 0.94; 95% conﬁdence interval (CI): 0.89–0.99 per 1.0 mmol L-1
increase] as well as CVD mortality (HR: 0.97; 95% CI: 0.88–1.07). The association with
IHD mortality (HR: 1.07; 95% CI: 0.92–1.24) was not linear but seemed to follow a
‘U-shaped’ curve, with the highest mortality <5.0 and 7.0 mmol L-1. Among men, the
association of cholesterol with mortality from CVD (HR: 1.06; 95% CI: 0.98–1.15) and in
total (HR: 0.98; 95% CI: 0.93–1.03) followed a ‘U-shaped’ pattern.
Conclusion Our study provides an updated epidemiological indication of possible errors
in the CVD risk algorithms of many clinical guidelines. If our ﬁndings are generalizable,
clinical and public health recommendations regarding the ‘dangers’ of cholesterol should
be revised. This is especially true for women, for whom moderately elevated cholesterol
(by current standards) may prove to be not only harmless but even beneﬁcial.
Introduction
It has long been considered ‘common knowledge’that total serum
cholesterol is an important and strong, independent risk factor for
cardiovascular disease (CVD) [1–4]. This association has been
deemed to be linear, meaning ‘the lower the total cholesterol level,
the better’. During the last decades, CVD prevention has been
marked by a trend of gradually lowering thresholds of risk deﬁni-
tions regarding cholesterol levels [2,5–8], in parallel with other
CVD risk factors such as hypertension and blood sugar [5,7,9–12].
Campaigns aimed at the general public have underlined the risks
associated with total cholesterol above 5.0 mmol L-1 (see, for
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under5.no).
In recent years, a ‘combined estimate’ [2,7,8,13–17] has
become the most widespread method for CVD risk evaluation, as
it is believed to have better predictive properties than the single
risk factor approach. Most combined estimates include the risk
factors of age, sex, smoking, blood pressure and serum cholesterol.
Additionally, the algorithms include, to a varying degree, other
factors such as diabetes, obesity, family history and cholesterol
subfractions [low-density lipoprotein (LDL) and high-density
lipoprotein (HDL) cholesterol] [2,5,7,8,12–17].
Some studies [18–22], including papers from our research
group [23,24], have problematized overestimation of CVD risk
in authoritative, preventive clinical guidelines. Both single risk
factors [24,25] and combined risk estimates have been addressed
[23,26]. We have shown that according to authoritative CVD
guidelines, 75% of the adult Norwegian population would be
deemed at risk for CVD and in need of clinical attention (advice
and supervision) [25,26]. Consequently, we have questioned the
theoretical basis of the guidelines. In the present study, we look
speciﬁcally at the validity of guidelines’ risk estimations involving
cholesterol. In particular, we challenge the widespread assumption
of a linear relationship between total cholesterol levels and disease
development (expressed as mortality in our analysis).
We are well aware of evidence indicating that cholesterol sub-
particles, including various lipoproteins, may have stronger asso-
ciations with CVD development than total cholesterol [27–34].
However, the emphasis on total cholesterol (as both a single risk
factor and an element in multiple risk estimates) still prevails in
many authoritative, clinical guidelines [1,7,17]. For instance, both
the 2003 and the 2007 European Guidelines on CVD prevention
state that ‘in general, total plasma cholesterol should be below 5,’
[2,16] and the risk charts in the same guidelines include total
cholesterol.
In the past decades, a number of studies have found a strong and
graded association between serum cholesterol and mortality from
ischaemic heart disease (IHD) [14,35–48]. Regarding total mor-
tality, however, the association has not been clear. Some studies
have found no association, and others have even suggested an
inverse relationship [38–41,43,49–61]. Some studies have shown
an inverse or a U-shaped association between cholesterol and
death from causes other than CVD, such as cancer [52,56,62,63].
The phrase ‘U-shaped association’ (alternatively ‘J-shaped’) indi-
cates that higher mortality (or incidences) can be observed both in
individuals with low and high levels of cholesterol compared with
individuals with levels in between. It is important to note, however,
that the phrase ‘U-shaped’ does not necessarily indicate that both
arms of the ‘U’are equal in terms of mortality rates or the propor-
tion of the population belonging to each arm.
Regarding the association between cholesterol and overall CVD
mortality, some studies have found no association or a U-shaped
or even an inverse association [37,58,61,64–67]. This has been
explained by an association with cerebral strokes (primarily haem-
orrhagic strokes), as opposed to heart disease [34,46,67–72]. Inter-
estingly, some studies have also found an inverse [55,67,73] or a
U-shaped [61,74–78] association with IHD incidence and mortal-
ity, primarily among individuals, aged 60 years and older.
The incidence, prevalence and mortality from CVD have
decreased substantially throughout the Western world in recent
decades [79,80]. There are also signiﬁcant time trend changes
regarding various risk factors for CVD [81–83]. Changes have
occurred, both regarding risk factors frequently included in com-
bined risk estimates [83–85] and for factors such as societal struc-
ture [86,87], pollution [88], television viewing [89] and dietary
habits [90,91]. These on-going changes are likely to alter the
predictive value of risk algorithms based on observational data
collected years or even decades ago (retrospective risk bias). As
cholesterol has become an essential part of lay-people’s basic
understanding of their health, and the prevalence of slightly
‘elevated’cholesterol levels is so high, we believe that it is impor-
tant to re-examine old assumptions regarding cholesterol as a risk
factor.
The aim of the present study was to document the strength and
validity of total serum cholesterol as a risk factor for mortality, as
deﬁned by current CVD prevention guidelines. For this purpose,
we used data from a well-deﬁned, general Norwegian population
without known CVD at baseline. We focused on deaths from
cardiovascular disease, IHD and death from all causes (total
mortality) within a follow-up period of 10 years.
Methods
Study population
All adults, aged 20 years or older and living in Nord-Trøndelag
County in Norway in 1995–1997, were invited to participate in the
second wave of the Nord-Trøndelag Health Study (HUNT 2).
Overall, 74% of women (34 786) and 65% of men (30 575) chose
to participate. The HUNT 2 population is ethnically homogeneous
(dominated by individuals of Nordic origin) and has been consid-
ered fairly representative of the total Norwegian population with
respect to demography, socio-economic factors, morbidity and
mortality, including mortality from CVD [92]. The HUNT 2 study
has been described in detail elsewhere (see http://www.ntnu.no/
hunt/english) [92].
For the purpose of the present analysis, the following HUNT 2
participants were excluded: 6780 individuals aged 75 years or
more at baseline (2815 men and 3965 women); 3430 individuals
(2207 men and 1223 women) with established CVD at baseline
(self-reported myocardial infarction, stroke or angina pectoris);
and 3064 persons with missing data on one or more of the follow-
ing variables: serum cholesterol, systolic blood pressure and
smoking status. Our calculations are thereby based on information
from 52 087 individuals (24 235 men and 27 852 women) aged
20–74 years and free from known CVD at baseline.
Study variables
In the HUNT 2 survey, total serum cholesterol was measured by
an enzymatic colorimetric cholesterol esterase method [92]. The
blood pressure of persons in a seated position was measured by a
specially trained personnel using Dinamap 845XT, based on oscil-
lometry. The cuff size was adjusted after measuring the arm cir-
cumference, and blood pressure was recorded as the mean values
of the second and third measurements performed consecutively at
the same visit. Smoking was deﬁned as daily smoking of ciga-
rettes, cigars or a pipe.
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The personal identity number of Norwegian citizens enabled
linking of HUNT 2 participant data to the Cause of Death Registry
at Statistics Norway (information on http://www.ssb.no/english/).
For the present analysis, each participant contributed person–time
from the date of clinical examination (August 1995–June 1997)
until 10 years of follow-up had been achieved (untilAugust 2005–
June 2007, depending on participation dates) or until the date of
death if this occurred in the follow-up period, making the oldest
participants of the study 84 years of age at the end of the follow-
up. The follow-up time came to a total of 510 297 person-years.
Death from CVD was deﬁned by the International Classiﬁcation of
Disease code for the primary diagnosis of death (ICD-9: 390-459;
ICD-10: I 00-I 99) as well as death from IHD (ICD-9: 410-414;
ICD-10: I 20-I 25).
Statistical analysis
The ﬁrst part of our analysis involved making a simple CVD risk
estimation chart to compare with the charts currently recom-
mended for clinical practice in Norway. We used the Systematic
Coronary Risk Evaluation (SCORE) chart of the European Society
of Cardiology [2,15] and the nationally adjusted chart used in the
Norwegian National Guidelines [17] as a reference. These charts
are intended to depict the 10-year risk of dying from CVD, given
the level of risk factors at baseline: sex, age, smoking status,
systolic blood pressure and total cholesterol. To have a meaningful
amount of data for each square of our chart, we based it on three
age groups (20–39, 40–59 and 60–74 years), two levels of systolic
blood pressure (<140 mm Hg vs. 140 mm Hg, in accordance
with guidelines), smokers vs. non-smokers, and two levels of total
cholesterol. Regarding cholesterol, the levels <5.5 mmol L-1 vs.
5.5 mmol L-1 were used (cut-off approximately 215 mg dL-1).
This cut-off point assigns 40% of participating males and 43% of
females to the ‘low level’ category. Using a cut-off point of
5.0 mmol L-1 (which guidelines [2,16] state that cholesterol
should be below) would have assigned only 24% of males and
27% of females to the lower cholesterol stratum. The median
cholesterol level of the participants was 5.7 mmol L-1 for both
genders. The observed mortality rates per 1000 person-years were
calculated for each square of the chart.
For the next part of our analysis, we used Cox proportional
hazard models to compute hazard ratios (HRs) for overall mortal-
ity and mortality from CVD and IHD, associated with different
levels of cholesterol at baseline. The precision of the estimated
associations was assessed by a 95% conﬁdence interval (CI).
Departure from the proportional hazard assumptions was evalu-
ated by Schoenfeld residuals.
We computed sex-speciﬁc HRs for cholesterol as a continuous
variable as well as a variable with four categories (<5.0, 5–5.9,
6.0–6.9 and 7.0 mmol L-1). We adjusted for the other variables
of the aforementioned chart, namely age (in the timescale), sys-
tolic blood pressure (as a continuous variable) and smoking status.
We also ran an alternative model including the same variables,
in addition to waist-to-hip ratio (WHR), level of physical activity,
self-reported diabetes mellitus and family history of CVD. The
categorical cholesterol variable was tested for linear as well as
quadratic trend. Finally, we conducted an analysis of cholesterol
as a dichotomous variable with the cut-off point of 5.5 mmol L-1,
stratiﬁed by smoking status, and an analysis of the effect of
smoking stratiﬁed by the dichotomous cholesterol variable for
comparison.
All statistical tests were two-sided and all analyses were
performed using Stata for Windows (version 11; StataCorp LP,
TX, USA).
Ethics statement
Each participant in the HUNT study signed a written consent
regarding the screening and the use of data for research purposes
as well as linking their data to other registers (subject to the
approval of the Norwegian Data Inspectorate). The study was
approved by the Norwegian Data Inspectorate and the Regional
Committee for Ethics in Medical Research.
Results
Figure 1 shows CVD mortality for the HUNT 2 population during
the 10-year follow-up period (mortality rates per 1000 person-
years), according to each level of the risk factors found in the
international SCORE system. This model showed a general trend
towards increased mortality for an increase in any of the included
risk factors, except for cholesterol, where no such association was
observed. The results were similar regarding all-cause mortality
and IHD mortality (data not shown).
Table 1 shows the sex-speciﬁc associations of different levels
of serum cholesterol with mortality, both total mortality and CVD
and IHD mortality. Among women, serum cholesterol had an
inverse association with all-cause mortality as well as CVD mor-
tality (although not reaching statistical signiﬁcance) (Table 1).The
association with IHD mortality appeared to follow a U-shaped
curve. Test for quadratic trend did not support the existence of a
U-shaped curve (P = 0.16).
Among men, cholesterol did not seem to be linearly associated
with mortality but rather the association followed a U-shaped
pattern, with the lowest mortality appearing in the second
cholesterol category (5.0–5.9 mmol L-1). This was apparent in
all mortality categories. Consequently, cholesterol analysed as a
continuous variable did not show a statistically signiﬁcant
linear association with mortality. Test for quadratic trend yielded
P = 0.01 for all-cause mortality (indicating a true U-curve), P =
0.055 for CVD (approaching statistical signiﬁcance) and P = 0.80
for IHD (practically excluding a U-curve). The associations
between cholesterol and mortality are visualized in Figs 2–4.
A sensitivity analysis adjusting for four additional risk factors
(WHR, physical activity and family history) revealed results of
no considerable difference from the ﬁrst model (adjusting for age,
smoking and systolic blood pressure) for either sex.
The association of a dichotomous cholesterol variable with
mortality, stratiﬁed by smoking status, is shown in Table 2.
The HRs relate to the risk of dying among individuals with high
serum cholesterol (5.5 mmol L-1) compared with those with
lower levels (<5.5 mmol L-1). Having cholesterol levels above
5.5 mmol L-1 was not associated with increased mortality, either
among smokers or among non-smokers.
Smoking, on the other hand, was strongly associated with
increased mortality in all mortality categories among both sexes
H. Petursson et al. Cholesterol and mortality in CVD risk algorithms
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for those with cholesterol below 5.5 mmol L-1.
Discussion
In this validation study of current guidelines for CVD prevention,
which is based on new epidemiological data from a large and
representative Norwegian population, we found total cholesterol
to be an overestimated risk factor.
Regarding the association between total cholesterol and mortal-
ity, our results generally indicated U-shaped or inverse linear
curves for total and CVD mortality. Only the association with
IHD among men could be interpreted as suggesting a positive,
linear trend.
Our results contradict the guidelines’ well-established demar-
cation line (5 mmol L-1) between ‘good’ and ‘too high’ levels
of cholesterol. They also contradict the popularized idea of a
positive, linear relationship between cholesterol and fatal disease.
Guideline-based advice regarding CVD prevention may thus
be outdated and misleading, particularly regarding many women
who have cholesterol levels in the range of 5–7 mmol L-1 and are
currently encouraged to take better care of their health.
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Figure 1 Ten-year incidence of fatal cardio-
vascular disease per 1000 person-years in the
population of Nord-Trøndelag (HUNT 2 study).
Table 1 Risk of death from all causes, cardiovascular disease and ischaemic heart disease among individuals aged 20–74; associations of total
cholesterol with mortality
Cholesterol
(mmol L
-1)
No. of
persons
All causes Cardiovascular disease Ischaemic heart disease
No. of
deaths
Adjusted* HR
(95% CI) Ptrend
No. of
deaths
Adjusted* HR
(95% CI) Ptrend
No. of
deaths
Adjusted* HR
(95% CI) Ptrend
Men
<5.0 5 918 208 1.00 (Reference) 58 1.00 (Reference) 24 1.00 (Reference)
5.0–5.9 8 021 410 0.77 (0.65–0.92) 132 0.80 (0.59–1.09) 65 0.94 (0.59–1.50)
6.0–6.9 6 658 500 0.84 (0.71–0.99) 168 0.87 (0.64–1.18) 85 1.06 (0.67–1.67)
7.0 3 638 329 0.89 (0.74–1.06) 0.90 128 1.05 (0.76–1.44) 0.25 57 1.12 (0.69–1.81) 0.39
per unit increase 24 235 1447 0.98 (0.93–1.03) 0.35 486 1.06 (0.98–1.15) 0.17 231 1.08 (0.96–1.22) 0.18
Women
<5.0 7 613 98 1.00 (Reference) 19 1.00 (Reference) 9 1.00 (Reference)
5.0–5.9 8 565 243 0.92 (0.72–1.17) 59 0.90 (0.53–1.52) 19 0.61 (0.27–1.38)
6.0–6.9 6 404 327 0.84 (0.66–1.06) 91 0.81 (0.49–1.35) 32 0.60 (0.28–1.30)
7.0 5 270 375 0.72 (0.57–0.92) 0.001 121 0.74 (0.44–1.22) 0.13 56 0.72 (0.34–1.51) 1.00
per unit increase 27 852 1043 0.94 (0.89–0.99) 0.02 290 0.97 (0.88–1.07) 0.53 116 1.07 (0.92–1.24) 0.37
*Adjusted for age (in the timescale), smoking (current vs. not) and systolic blood pressure (continuous).
CI, conﬁdence interval; HR, hazard ratio.
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cal data and clinical guidelines [2,16,17], suggesting a linear rela-
tion between total cholesterol and mortality from CVD is in accord
with other studies [61,66,67].
The main strengths of our study are the prospective and com-
prehensive nature of the HUNT 2 survey, its good participation
rates, and representativeness of the entire Norwegian population
of similar, i.e. Nordic, origin. A corresponding weakness is the
lack of immediate generalizability to Norwegians with other
ethnic backgrounds.Another potential weakness of our study is the
lack of information about cholesterol-lowering drug treatment
among the participants. However, this is unlikely to be an impor-
tant source of bias as our population was free from CVD at base-
line, and cholesterol-lowering drugs were not recommended for
primary prevention in the study period.
It is possible that the Norwegian HUNT 2 population differs
somewhat from earlier study populations in levels of CVD risk
factors and mortality, and that this may affect (or confound) the
association of cholesterol with mortality. Norway is an afﬂuent
country, and Norwegians are currently one of the longest lived
people in the world [93]. The rate of smoking among men is
relatively low, by international comparison [93]. The stable
social structure could also play a part, including a well-functioning
health care system with good access and coverage for all.
Various studies have shown cholesterol, smoking and high
blood pressure to have a multiplicative effect on IHD risk rather
than an additive effect [94–97]. It may be that cholesterol acts
differently as a risk factor for IHD than previously believed,
at least in certain risk factor combinations and/or under certain
Hazard
ratio
1.40
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1.20
1.00
0.80
0.60
<5.0 5.0–5.9
Total cholesterol (mmol L−1)
6.0–6.9 ≥7.0
Figure 2 Risk of death (all causes) associated with different levels
of total cholesterol. Hazard ratios and 95% conﬁdence intervals for
men (blue box) and women (red diamond) separately. Adjusted for
age, smoking and systolic blood pressure.
Hazard
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1.40
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1.20
1.00
0.80
0.60
<5.0 5.0–5.9
Total cholesterol (mmol L−1)
6.0–6.9 ≥7.0
Figure 3 Risk of death from cardiovascular disease associated with
different levels of total cholesterol. Hazard ratios and 95% conﬁdence
intervals for men (blue box) and women (red diamond). Adjusted for
age, smoking and systolic blood pressure.
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Figure 4 Risk of death from ischaemic heart disease associated with
different levels of total cholesterol. Hazard ratios and 95% conﬁdence
intervals for men (blue box) and women (red diamond). Adjusted for
age, smoking and systolic blood pressure.
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tioned earlier. At least in some settings, cholesterol may represent
a risk marker and/or a weak risk factor rather than an important
one. More valid risk factors might be found by further investiga-
tion of lipoproteins and/or other subparticles of cholesterol, but
the same dilemmas may arise in relation to those entities. What
appears evident, however, is that more updated and complex
disease prediction models are needed.
Regarding the immediate future of guidelines and combined
risk estimates for CVD, we envisage three options: ﬁrst, IHD
Table 2 Risk of death from all causes, cardiovascular disease and ischaemic heart disease depending on smoking status for individuals 20–74 years
old; hazard ratios for high* total cholesterol compared with low cholesterol levels
Cause of
death
Level of
cholesterol*
Men Women
No. of
persons
No. of
deaths
Adjusted
† HR
(95% CI)
No. of
persons
No. of
deaths
Adjusted
† HR
(95% CI)
All causes
Smokers High 4726 476 0.87 (0.73–1.03) 5 406 339 1.00 (0.77–1.31)
Low 2680 180 1.00 (Reference) 3 795 75 1.00 (Reference)
Non-smokers High 9724 573 0.94 (0.80–1.10) 10 485 503 0.74 (0.60–0.91)
Low 7105 218 1.00 (Reference) 8 166 126 1.00 (Reference)
CVD
Smokers High 4726 181 0.92 (0.68–1.24) 5 406 94 1.09 (0.60–2.00)
Low 2680 58 1.00 (Reference) 3 795 13 1.00 (Reference)
Non-smokers High 9724 182 0.91 (0.68–1.21) 10 485 160 1.00 (0.63–1.57)
Low 7105 65 1.00 (Reference) 8 166 23 1.00 (Reference)
IHD
Smokers High 4726 89 1.03 (0.66–1.59) 5 406 46 1.19 (0.48–2.93)
Low 2680 26 1.00 (Reference) 3 795 6 1.00 (Reference)
Non-smokers High 9724 88 1.00 (0.65–1.53) 10 485 56 0.96 (0.45–2.06)
Low 7105 28 1.00 (Reference) 8 166 8 1.00 (Reference)
*Comparison of high (5.5 mmol L
-1) vs. low (<5.5 mmol L
-1) total cholesterol.
†Adjusted for age (in the timescale), smoking (current vs. not) and systolic blood pressure.
CVD, cardiovascular disease; CI, conﬁdence interval; HR, hazard ratio; IHD, ischaemic heart disease.
Table 3 Risk of death from all causes, cardiovascular disease and ischaemic heart disease depending on levels of total cholesterol for individuals
20–74 years old; hazard ratios for smoking compared with non-smoking
Cause of death Smoking status
Men Women
No. of
persons
No. of
deaths
Adjusted* HR
(95% CI)
No. of
persons
No. of
deaths
Adjusted* HR
(95% CI)
All causes
High
† cholesterol Smoking 4726 476 2.09 (1.71–2.55) 5 406 339 1.72 (1.29–2.30)
Non-smoking 2680 180 1.00 (Reference) 3 795 75 1.00 (Reference)
Low
‡ cholesterol Smoking 9724 573 1.99 (1.76–2.24) 10 485 503 2.16 (1.87–2.48)
Non-smoking 7105 218 1.00 (Reference) 8 166 126 1.00 (Reference)
CVD
High cholesterol Smoking 4726 181 2.30 (1.61–3.29) 5 406 94 1.82 (0.91–3.64)
Non-smoking 2680 58 1.00 (Reference) 3 795 13 1.00 (Reference)
Low cholesterol Smoking 9724 182 2.44 (1.98–3.00) 10 485 160 2.24 (1.73–2.91)
Non-smoking 7105 65 1.00 (Reference) 8 166 23 1.00 (Reference)
IHD
High cholesterol Smoking 4726 89 2.28 (1.34–3.90) 5 406 46 2.35 (0.80–6.95)
Non-smoking 2680 26 1.00 (Reference) 3 795 6 1.00 (Reference)
Low cholesterol Smoking 9724 88 2.42 (1.80–3.25) 10 485 56 3.08 (2.07–4.58)
Non-smoking 7105 28 1.00 (Reference) 8 166 8 1.00 (Reference)
*Adjusted for age (in the timescale), smoking (current vs. not) and systolic blood pressure.
†High total cholesterol 5.5 mmol L
-1.
‡Low total cholesterol <5.5 mmol L
-1.
CVD, cardiovascular disease; CI, conﬁdence interval; HR, hazard ratio; IHD, ischaemic heart disease.
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appropriate end point for the current risk estimates. However, our
results (Table 1) indicate that even such a limited focus would be
problematic, at least for women. Alternatively, total cholesterol
could be excluded from the risk estimates, potentially being
replaced either by nothing or by some different subparticle(s) of
cholesterol with better predictive properties, such as HDLor HDL/
total cholesterol [2,8,16]. Finally, future risk estimates may be
based on more nuanced statistical models, allowing for gender-
and age-speciﬁc associations between cholesterol and disease
development (mortality).
The Norwegian guidelines for prevention of CVD [17] include
a risk estimation model developed on the basis of Norwegian
population data [21]. This model assumes a linear association of
cholesterol with CVD mortality, and the authors do not indicate
that any evaluation of the linearity of the association has taken
place, i.e. an evaluation of a possible U-shaped association. Selmer
et al. included participants, aged 20–67, in their study, while we
included people up to 74 years old, and the U-shaped association
has been most prominent in studies, including participants over
age 60. This difference should, however, be minimized by the
statistical adjustments made for the effects of age. Besides the
included age groups, there is no reason to believe that the Norwe-
gian population data underlying the Norwegian guidelines differ
considerably from the HUNT 2 population.
To address the question of whether the U-shaped association
was age-dependent in the HUNT population, we performed an
age-stratiﬁed Cox-regression analysis post-hoc. The results indi-
cated a U-shaped association of cholesterol with CVD mortality
among men aged 40–74, and an inverse association among women
aged 60–74. Because of limited statistical power, we refrain from
emphasizing these results. Seen in the light of previous studies
[37,55,58,61,64–66,73–77], it is possible that a U-shaped associa-
tion is primarily a phenomenon related to people aged 60 years
and older.
Our smoking-stratiﬁed analysis (Table 2) indicated that the
U-shaped association can possibly be found among both smokers
and non-smokers, as no considerable difference was observed
between these two strata. Analysis with more categories of cho-
lesterol levels would have been preferable here, but due to limited
statistical power, we refrain from further analyses post-hoc.
In contrast to cholesterol, the detrimental effect of smoking was
clearly evident even after stratifying for cholesterol levels
(Table 3). This emphasizes the importance of smoking as a CVD
risk factor compared with cholesterol.
Conclusions
Based on epidemiological analysis of updated and comprehensive
population data, we found that the underlying assumptions regard-
ing cholesterol in clinical guidelines for CVD prevention might be
ﬂawed: cholesterol emerged as an overestimated risk factor in our
study, indicating that guideline information might be misleading,
particularly for women with ‘moderately elevated’ cholesterol
levels in the range of 5–7 mmol L-1. Our ﬁndings are in good
accord with some previous studies. A potential explanation of the
lack of accord between clinical guidelines and recent population
data, including ours, is time trend changes for CVD/IHD and
underlying causal (risk) factors.
‘Know your numbers’ (a concept pertaining to medical risk
factor levels, including cholesterol) is currently considered part of
responsible citizenship, as well as an essential element of preven-
tive medical care. Many individuals who could otherwise call
themselves healthy struggle conscientiously to push their choles-
terol under the presumed ‘danger’ limit (i.e. the recommended
cut-off point of 5 mmol L-1), coached by health personnel, per-
sonal trainers and caring family members. Massive commercial
interests are linked to drugs and other remedies marketed for this
purpose. It is therefore of immediate and wide interest to ﬁnd out
whether our results are generalizable to other populations.
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